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Abstract
Objective
Several studies on associations between human leukocyte antigen (HLA) allele frequencies
and susceptibility to systemic sclerosis (SSc) have been reported. Anti-centromere antibod-
ies (ACA) and anti-topoisomerase I antibodies (ATA) are found in SSc patients. Here, we
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sought to identify HLA alleles associated with SSc in Japanese, and explored their associa-
tions with SSc phenotypes including the presence of autoantibodies.
Methods
Associations of HLA-DRB1, DQB1, and DPB1 were analyzed in 463 Japanese SSc patients
and 413 controls.
Results
We found that DRB1*13:02 (P = 0.0011, Pc = 0.0319, odds ratio [OR] 0.46, 95% confidence
interval [CI] 0.29–0.73), DRB1*14:06 (P = 6.60X10-5, Pc = 0.0020, OR 0.05, 95%CI 0.01–
0.41), DQB1*03:01 (P = 0.0009, Pc = 0.0150, OR 0.56, 95%CI 0.40–0.79), and
DPB1*02:01 (P = 5.16X10-6, Pc = 8.77X10-5, OR 0.52, 95%CI 0.39–0.69) were protectively
associated with SSc. In addition, these four alleles seemed to be independently associated
with the protection against the susceptibility of SSc. On the other hand, we could not find
predisposing alleles for overall SSc. With respect to SSc subsets, a tendency for these four
alleles to be protectively associated was observed. However, there was a significant associ-
ation between DRB1*01:01, DRB1*10:01, DQB1*05:01, and DPB1*04:02 and the suscep-
tibility to SSc with ACA. On the other hand, the presence of DRB1*15:02, DQB1*06:01,
DPB1*03:01, and DPB1*09:01 was associated with SSc with ATA.
Conclusion
Thus, the present study has identified protective associations of the four HLA class II alleles
with overall Japanese SSc and predisposing associations of HLA class II alleles with Japa-
nese SSc subsets.
Introduction
Systemic sclerosis (SSc) is a complex autoimmune disease of unknown etiology that is charac-
terized by fibrosis of the skin and internal organs, small-vessel vasculopathy, and the produc-
tion of anti-nuclear antibodies. It is a chronic autoimmune disease, susceptibility to which is
associated with genetic and environmental factors [1,2]. Genetic risk factors for SSc include
alleles of the loci HLA-DRB1, DQB1, DPB1, DPB2, IRF5, STAT4, CD247, IRF4, and others
[1,3,4,5]. Thus, a functional role of these polymorphisms in SSc has been suggested, as well as
relationships with other autoimmune diseases such as rheumatoid arthritis or systemic lupus
erythematosus. In particular, skewed frequencies of human leukocyte antigen (HLA) alleles are
known to be associated with SSc. Different HLA class II alleles appear to be associated with SSc
susceptibility in different ethnic groups, such as HLA-DRB111:04, DQB103:01, or DQB126
epi (DQB1 alleles encoding a non-leucine residue at position 26) in Europeans[2,6,7],
DRB108:04, DQB103:01, or DPB113:01 in African-Americans [6], and DRB115:02,
DQB105:01, and DPB103:01 in Asians [8,9,10,11,12,13,14].
SSc presents with several specific autoantibodies including anti-centromere antibodies
(ACA) [15] and anti-topoisomerase I antibodies (ATA, also termed Scl-70) [16]. ACA are pres-
ent in a subset of patients with SSc who have limited cutaneous SSc (lcSSc). This is character-
ized by skin thickening that is relatively restricted to the fingers and hands, with less severe
HLA and SSc in Japan
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internal organ involvement. ATA are present in an SSc subset having diffuse cutaneous SSc
(dcSSc), in which skin lesions are extensive and progressive, and serious internal organ involve-
ment is observed. DQB105:01, DQB126 epi are associated with SSc with ACA in people of
European descent [6] and DQB105:01 in Japanese [9]. Several studies have also shown that
certain DRB1 or DPB1 alleles are associated with SSc with ATA; thus, DPB113:01 is associated
with SSc with ATA in Europeans [6] and DRB115:02 and DPB109:01 in Japanese [9].
Here, we sought HLA alleles predisposing and protective to SSc in Japanese, and explored
their associations with SSc phenotypes including the presence of autoantibodies.
Materials and Methods
Patients and healthy controls
SSc patients were recruited at Sagamihara Hospital, Yokohama Minami Kyosai Hospital, Tama
Medical Center, Kitasato University, Komagome Hospital, Teikyo University, Himeji Medical
Center, Morioka Hospital, Kyushu Medical Center, Nagoya Medical Center, Nagasaki Medical
Center, University of Tsukuba, and Kanazawa University. Healthy controls (n = 413; mean
age ± SD, 41.4 ± 12.6 years, 62 male [14.0%]) were recruited without matching at Sagamihara
Hospital, Teikyo University, and Kanazawa University or by the Pharma SNP Consortium
(Tokyo, Japan) [17]. All patients and healthy individuals were native Japanese living in Japan.
All patients with SSc fulfilled the American College of Rheumatology criteria for SSc [18] and
were classified as dcSSc and lcSSc according to the classification criteria by LeRoy et al. [19].
ACA was detected using Mesacup-2 test CENP-B enzyme-linked immunosorbent assay
(ELISA, Medical & Biological Laboratories, Nagoya, Japan). ATA was detected using Mesacup-
3 test Scl-70 ELISA (Medical & Biological Laboratories) or Ouchterlony double immunodiffu-
sion method (TFB, Hachioji, Japan). This study was reviewed and approved by the research
ethics committees of each participating institute as follows: Sagamihara Hospital Research Eth-
ics Committee, Yokohama Minami Kyosai Hospital Research Ethics Committee, Tama Medi-
cal Center Research Ethics Committee, Kitasato University Research Ethics Committee,
Komagome Hospital Research Ethics Committee, Teikyo University Research Ethics Commit-
tee, Himeji Medical Center Research Ethics Committee, Morioka Hospital Research Ethics
Committee, Kyushu Medical Center Research Ethics Committee, Nagoya Medical Center
Research Ethics Committee, Nagasaki Medical Center Research Ethics Committee, Kanazawa
University Research Ethics Committee, and University of Tsukuba Research Ethics Committee.
Written informed consent was obtained from all study participants. This study was conducted
in accordance with the principles expressed in the Declaration of Helsinki.
Genotyping
Genotyping ofHLA-DRB1, DQB1, and DPB1 was performed by the polymerase chain reaction
technique with sequence-specific oligonucleotide probes (WAKFlow HLA typing kits, Waku-
naga, Hiroshima, Japan), using the Bio-Plex 200 system (Bio-Rad, Hercules, CA). DQB126 epi
alleles are DQB103:01, 04:01, 04:02, 05:01, 05:02, 05:03, and 06:01. Results of genotyping
for some of the healthy controls were reported previously [20,21,22].
Statistical analysis
Differences of SSc characteristics were analyzed by Student's t-test or Fisher’s exact test using
2X2 contingency tables. The Hardy-Weinberg exact tests were performed by the Markov chain
method under the condition of 10000 each of dememorization, batches, and iterations per
batch (Genepop on the web; http://genepop.curtin.edu.au/) [23]. The statistical power in each
HLA and SSc in Japan
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condition of allele carrier frequency and odds ratio was calculated on the sample size of this
study (463 overall SSc patients and 413 controls, S1 Fig) by PS: Power and Sample Size Calcula-
tion version 3.1.2 (http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize) [24]. Differ-
ences of allele carrier frequencies were analyzed by Fisher’s exact test using 2X2 contingency
tables under the dominant model. Adjustment for multiple comparisons was performed using
the Bonferroni method. Corrected P (Pc) values were calculated by multiplying the P value by
the number of alleles tested. Relative predispositional effects (RPE) were analyzed by sequential
elimination of carriers of each allele with the strongest association [25]. To examine whether
each protective HLA class II allele independently contributes to the protection of SSc, multiple
logistic regression analysis under the additive model was employed and the deviation from 0
was evaluated for coefficients by the Wald test. DRB1-DQB1-DPB1 haplotype frequencies were
estimated using the expectation-maximization method by SNPAlyze ver.8.0.4 Pro software
(Dynacom, Chiba, Japan). P values were calculated by permutation test (100000 permutations).
Differences of amino acid residue carrier frequencies (amino acid residue carrier vs. non-car-
rier) were analyzed by Fisher’s exact test using 2X2 contingency tables under the dominant
model on the detected polymorphic amino acid positions in the β1 domain of HLA-DRβ,
DQβ, and DPβ chains. Adjustment for multiple comparisons was performed using the Bonfer-
roni method. Pc values were calculated by multiplying the P value by the number of amino
acid positions tested.
Results
Clinical features of the SSc patients
Characteristics of the SSc patients are described in Table 1. Mean age and ACA positivity in
dcSSc were lower than in lcSSc. ATA positivity and percentage of male were higher in dcSSc
than lcSSc.
HLA association analysis of SSc patients
HLA-DRB1, DQB1, and DPB1 genotyping was performed in SSc patients and healthy controls
to compare carrier frequencies of each allele. No deviation from Hardy-Weinberg equilibrium
was detected in the controls (DRB1: P = 0.4327, DQB1: P = 0.2136, DPB1: P = 0.7464, all locus:
P = 0.5000), though a deviation was observed in the overall SSc patients (DRB1: P = 0.1017,
DQB1: P = 0.0769, DPB1: P = 0.0260, all locus: P = 0.0093). A significant protective association
was found for DRB113:02 (P = 0.0011, Pc = 0.0319, odds ratio [OR] 0.46, 95% confidence
interval [CI] 0.29–0.73, Table 2) and DRB114:06 (P = 6.60X10-5, Pc = 0.0020, OR 0.05, 95%CI
0.01–0.41, Table 2) with SSc. A significant association with resistance to SSc was also found for
Table 1. Characteristics of the SSc patients.
SSc dcSSc lcSSc P
Number 463 157 266
Mean age, years (SD) 58.4 (13.5) 54.5 (14.9) 61.0 (12.0) *4.65X10-6
Male, n (%) 50 (10.9) 29 (18.5) 19 (7.2) 0.0007
ACA positive, n (%) 194 (44.9) 20 (12.9) 167 (65.0) 1.73X10-26
ATA positive, n (%) 119 (27.4) 85 (54.5) 27 (10.5) 3.17X10-22
SSc: systemic sclerosis, dcSSc: diffuse cutaneous SSc, lcSSc: limited cutaneous SSc, ACA: anti-centromere antibodies, ATA: anti-topoisomerase I
antibodies. Association was tested between dcSSc and lcSSc by Fisher's exact test using 2X2 contingency tables or Student's t-test.
* Student's t-test was employed.
doi:10.1371/journal.pone.0154255.t001
HLA and SSc in Japan
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the DR6 serological group (DRB113 and DRB114, P = 7.08X10-6, OR 0.49, 95%CI 0.36–0.67,
Table 2). We further explored associations between DRB1 alleles and SSc using RPE testing by
sequential elimination of carriers of each allele with the strongest association (Table 2, right
column). The prime strongest association was between SSc and DRB114:06, followed by
13:02, 10:01, 04:03, and 04:07. A protective association between the carrier frequency of
DQB103:01 (P = 0.0009, Pc = 0.0150, OR 0.56, 95% CI 0.40–0.79, Table 3) or DPB102:01
(P = 5.16X10-6, Pc = 8.77X10-5, OR 0.52, 95% CI 0.39–0.69, Table 3) and SSc was detected. The
associations between DQB1 or DPB1 alleles and SSc using RPE were also analyzed. RPE were
tested by sequential elimination of carriers of each of the DQB1 alleles DQB103:01, 06:04,
and 06:02; DPB1 alleles DPB102:01 and 03:01, respectively. No statistically significant pre-
disposing associations were found for DQB126 epi (P = 0.2443, OR 1.24) or any HLA class II
Table 2. HLA-DRB1 allele carrier frequencies in the SSc patients and the healthy controls.
Case (n = 463) Control (n = 413) P OR Pc 95%CI P (RPE)
DRB1*01:01 65 (14.0) 42 (10.2) 0.0979 1.44 NS
DRB1*03:01 1 (0.2) 2 (0.5) 0.6044 0.44 NS
DRB1*04:01 10 (2.2) 7 (1.7) 0.8071 1.28 NS
DRB1*04:03 39 (8.4) 19 (4.6) 0.0288 1.91 0.8633 (1.08–3.36) 0.0343
DRB1*04:04 6 (1.3) 0 (0.0) 0.0322 11.75 0.9672 (0.66–209.22)
DRB1*04:05 94 (20.3) 87 (21.1) 0.8023 0.95 NS
DRB1*04:06 31 (6.7) 34 (8.2) 0.4390 0.80 NS
DRB1*04:07 11 (2.4) 3 (0.7) 0.0610 3.33 NS 0.0439
DRB1*04:10 23 (5.0) 14 (3.4) 0.3129 1.49 NS
DRB1*07:01 7 (1.5) 3 (0.7) 0.3490 2.10 NS
DRB1*08:02 56 (12.1) 38 (9.2) 0.1896 1.36 NS
DRB1*08:03 79 (17.1) 61 (14.8) 0.4059 1.19 NS
DRB1*08:09 0 (0.0) 1 (0.2) 0.4715 0.30 NS
DRB1*09:01 116 (25.1) 105 (25.4) 0.9379 0.98 NS
DRB1*10:01 15 (3.2) 2 (0.5) 0.0027 6.88 0.0820 (1.56–30.27) 0.0059
DRB1*11:01 17 (3.7) 22 (5.3) 0.2540 0.68 NS
DRB1*12:01 26 (5.6) 29 (7.0) 0.4058 0.79 NS
DRB1*12:02 7 (1.5) 10 (2.4) 0.3407 0.62 NS
DRB1*13:01 4 (0.9) 5 (1.2) 0.7419 0.71 NS
DRB1*13:02 32 (6.9) 57 (13.8) 0.0011 0.46 0.0319 (0.29–0.73) 0.0007
DRB1*14:03 15 (3.2) 21 (5.1) 0.1772 0.63 NS
DRB1*14:04 0 (0.0) 1 (0.2) 0.4715 0.30 NS
DRB1*14:05 21 (4.5) 14 (3.4) 0.4900 1.35 NS
DRB1*14:06 1 (0.2) 16 (3.9) 6.60X10-5 0.05 0.0020 (0.01–0.41) 6.60X10-5
DRB1*14:07 0 (0.0) 1 (0.2) 0.4715 0.30 NS
DRB1*14:29 1 (0.2) 0 (0.0) 1.0000 2.68 NS
DRB1*14:54 23 (5.0) 28 (6.8) 0.3117 0.72 NS
DRB1*15:01 55 (11.9) 68 (16.5) 0.0521 0.68 NS
DRB1*15:02 120 (25.9) 89 (21.5) 0.1323 1.27 NS
DRB1*16:02 5 (1.1) 5 (1.2) 1.0000 0.89 NS
DR6 91 (19.7) 137 (33.2) 7.08X10-6 0.49 (0.36–0.67)
SSc: systemic sclerosis, OR: odds ratio, CI: conﬁdence interval, Pc: corrected P value, NS: not signiﬁcant, RPE: relative predispositional effects. Allele
carrier frequencies are shown in parenthesis (%). Association was tested by Fisher's exact test using 2X2 contingency tables under the dominant model.
RPE were tested by sequential elimination of carriers of each of the alleles DRB1*14:06, *13:02, *10:01, *04:03, and *04:07.
doi:10.1371/journal.pone.0154255.t002
HLA and SSc in Japan
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alleles. Thus, lower carrier frequencies of the four class II alleles, DRB113:02, DRB114:06,
DQB103:01, and DPB102:01, were present in SSc patients.
DRB1, DQB1, and DPB1 alleles are in linkage disequilibrium. In order to elucidate which of
the four protective alleles was responsible for the observed protective associations, conditional
logistic regression analysis between them in SSc was performed (Table 4). The association of
DRB113:02 remained significant, when conditioned on DRB114:06, DQB103:01, or
DPB102:01. Similarly, the association of DRB114:06 still remained significant, when condi-
tioned on DRB113:02, DQB103:01, or DPB102:01. The significant association of
Table 3. HLA-DQB1 andDPB1 allele carrier frequencies in the SSc patients and the healthy controls.
Case (n = 463) Control (n = 413) P OR Pc 95%CI P (RPE)
DQB1*02:01 1 (0.2) 2 (0.5) 0.6044 0.44 NS
DQB1*02:02 7 (1.5) 3 (0.7) 0.3490 2.10 NS
DQB1*03:01 67 (14.5) 96 (23.2) 0.0009 0.56 0.0150 (0.40–0.79) 0.0009
DQB1*03:02 112 (24.2) 83 (20.1) 0.1666 1.27 NS
DQB1*03:03 124 (26.8) 111 (26.9) 1.0000 1.00 NS
DQB1*03:06 1 (0.2) 0 (0.0) 1.0000 2.68 NS
DQB1*04:01 91 (19.7) 86 (20.8) 0.6743 0.93 NS
DQB1*04:02 51 (11.0) 29 (7.0) 0.0457 1.64 0.7312 (1.02–2.64)
DQB1*05:01 79 (17.1) 44 (10.7) 0.0064 1.73 0.1030 (1.16–2.56)
DQB1*05:02 16 (3.5) 16 (3.9) 0.8572 0.89 NS
DQB1*05:03 31 (6.7) 34 (8.2) 0.4390 0.80 NS
DQB1*06:01 185 (40.0) 144 (34.9) 0.1247 1.24 NS
DQB1*06:02 54 (11.7) 65 (15.7) 0.0929 0.71 NS 0.0485
DQB1*06:03 4 (0.9) 6 (1.5) 0.5293 0.59 NS
DQB1*06:04 30 (6.5) 50 (12.1) 0.0046 0.50 0.0741 (0.31–0.81) 0.0010
DQB1*06:09 3 (0.6) 6 (1.5) 0.3198 0.44 NS
DPB1*02:01 128 (27.6) 175 (42.4) 5.16X10-6 0.52 8.77X10-5 (0.39–0.69) 5.16X10-6
DPB1*02:02 39 (8.4) 33 (8.0) 0.9020 1.06 NS
DPB1*03:01 65 (14.0) 35 (8.5) 0.0105 1.76 0.1793 (1.14–2.72) 0.0315
DPB1*04:01 31 (6.7) 41 (9.9) 0.0858 0.65 NS
DPB1*04:02 92 (19.9) 65 (15.7) 0.1133 1.33 NS
DPB1*05:01 272 (58.7) 250 (60.5) 0.6293 0.93 NS
DPB1*06:01 9 (1.9) 3 (0.7) 0.1511 2.71 NS
DPB1*09:01 124 (26.8) 82 (19.9) 0.0167 1.48 0.2844 (1.07–2.03)
DPB1*13:01 28 (6.0) 20 (4.8) 0.4605 1.26 NS
DPB1*14:01 11 (2.4) 8 (1.9) 0.8171 1.23 NS
DPB1*17:01 4 (0.9) 3 (0.7) 1.0000 1.19 NS
DPB1*19:01 5 (1.1) 2 (0.5) 0.4566 2.24 NS
DPB1*25:01 0 (0.0) 1 (0.2) 0.4715 0.30 NS
DPB1*38:01 2 (0.4) 0 (0.0) 0.5011 4.48 NS
DPB1*41:01 3 (0.6) 2 (0.5) 1.0000 1.34 NS
DPB1*47:01 1 (0.2) 0 (0.0) 1.0000 2.68 NS
DPB1*113:01 0 (0.0) 1 (0.2) 0.4715 0.30 NS
SSc: systemic sclerosis, OR: odds ratio, CI: conﬁdence interval, Pc: corrected P value, NS: not signiﬁcant, RPE: relative predispositional effects. Allele
carrier frequencies are shown in parenthesis (%). Association was tested by Fisher's exact test using 2X2 contingency tables under the dominant model.
RPE were tested by sequential elimination of carriers of each of the DQB1 alleles DQB1*03:01, *06:04, and *06:02; DPB1 alleles DPB1*02:01 and
*03:01, respectively.
doi:10.1371/journal.pone.0154255.t003
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DQB103:01 was observed, when conditioned on DRB113:02, DRB114:06, or DPB102:01.
The significant association of DPB102:01 was also detected, when conditioned on
DRB113:02, DRB114:06, or DQB103:01. Thus, significant protective associations for the four
alleles with SSc were observed, when conditioned on each other, indicating an independent
role for each protective allele in SSc.
When haplotype frequencies were compared between SSc patients and controls, a tendency
for four haplotypes (DRB115:01-DQB106:02-DPB102:01,
DRB113:02-DQB106:04-DPB104:01, DRB104:06-DQB103:02-DPB102:01,
DRB113:02-DQB106:04-DPB102:01) to be protectively associated was observed (S1 Table).
These four protective haplotypes include the abovementioned independent protective alleles.
HLA associations in SSc patients with ACA or ATA
We tested whetherHLA class II alleles were associated with SSc with ACA. A significant associ-
ation with susceptibility to SSc with ACA was found for the DRB101:01 and DRB110:01
alleles (P = 0.0001, Pc = 0.0042, OR 2.52, 95%CI 1.58–4.01; P = 0.0003, Pc = 0.0097, OR 11.17,
95%CI 2.42–51.48, respectively, S2 Table). A strong predisposing association between the car-
rier frequency of DQB105:01 and SSc with ACA (P = 1.18X10-6, Pc = 1.89X10-5, OR 3.07, 95%
CI 1.97–4.80, S3 Table) was detected. On the other hand, DQB103:01 was associated with
resistance to SSc with ACA (P = 1.05X10-5, Pc = 0.0002, OR 0.32, 95%CI 0.18–0.55), despite
the fact that this allele is known to be associated with susceptibility to SSc with ACA in Europe-
ans [6]. DPB104:02 was associated with SSc with ACA (P = 0.0001, Pc = 0.0020, OR 2.23, 95%
CI 1.48–3.35, S4 Table). A tendency for the four class II alleles, DRB113:02, DRB114:06,
DQB103:01, and DPB102:01, to be protectively associated with SSc with ACA was also
observed (S2, S3 and S4 Tables). The similar tendency for the ACA associated alleles to be asso-
ciated with lcSSc was observed (S2, S3 and S4 Tables), though it was weaker.
We then compared the allele carrier frequencies of DRB1, DQB1, and DPB1 in SSc with
ATA with their frequencies in healthy controls. A significant association with susceptibility to
SSc with ATA was found for the DRB115:02 allele (P = 7.22X10-9, Pc = 2.02X10-7, OR 3.58,
95%CI 2.33–5.50, S2 Table). A predisposing association between the carrier frequency of
DQB106:01 and SSc with ATA (P = 3.20X10-5, Pc = 0.0005, OR 2.41, 95%CI 1.59–3.64, S3
Table) was detected. DQB106:04 was associated with resistance to SSc with ATA
(P = 2.95X10-5, Pc = 0.0004, OR 0.06, 95%CI 0.01–0.45) and it was known that DQB106:04
and protective DRB113:02 are in strong linkage disequilibrium [26]. DPB103:01 and
DPB109:01 are associated with SSc with ATA (P = 3.42X10-5, Pc = 0.0006, OR 3.32, 95%CI
Table 4. Conditional logistic regression analysis between the four protective HLA alleles in SSc.
HLA allele Unconditioned Conditioned on
DRB1*13:02
Conditioned on
DRB1*14:06
Conditioned on
DQB1*03:01
Conditioned on
DPB1*02:01
P OR (95%CI) Padjusted ORadjusted
(95%CI)
Padjusted ORadjusted
(95%CI)
Padjusted ORadjusted
(95%CI)
Padjusted ORadjusted
(95%CI)
DRB1*13:02 0.0006 0.48(0.31–0.73) NA NA 0.0005 0.47 (0.30–0.71) 0.0002 0.45 (0.29–0.69) 0.0006 0.47 (0.31–0.73)
DRB1*14:06 0.0046 0.05(0.01–0.41) 0.0040 0.05 (0.01–0.39) NA NA 0.0127 0.07 (0.01–0.57) 0.0046 0.05 (0.01–0.40)
DQB1*03:01 0.0013 0.59(0.43–0.82) 0.0005 0.56 (0.41–0.78) 0.0264 0.69 (0.50–0.96) NA NA 0.0019 0.60 (0.43–0.83)
DPB1*02:01 8.91X10-6 0.58(0.46–0.74) 8.71X10-6 0.58 (0.45–0.74) 9.87X10-6 0.58 (0.45–0.74) 1.22X10-5 0.58 (0.46–0.74) NA NA
SSc: systemic sclerosis, OR: odds ratio, CI: conﬁdence interval, NA not applicable. P, OR, 95%CI, Padjusted, and ORadjusted were calculated by logistic
regression analysis under the additive model.
doi:10.1371/journal.pone.0154255.t004
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1.92–5.74; P = 7.82X10-12, Pc = 1.33X10-10, OR 4.54, 95%CI 2.94–7.01, respectively, S4 Table).
A protective association for DPB102:01 and DPB104:01 was detected with SSc with ATA
(P = 2.06X10-8, Pc = 3.50X10-7, OR 0.24, 95%CI 0.14–0.42; P = 4.18X10-5, Pc = 0.0007, OR
0.04, 95%CI 0.00–0.62, respectively, S4 Table). A tendency for the four class II alleles,
DRB113:02, DRB114:06, DQB103:01, and DPB102:01, to be protectively associated with SSc
with ATA was observed (S2, S3 and S4 Tables). The similar tendency for the ATA associated
alleles to be associated with dcSSc was observed (S2, S3 and S4 Tables). Thus, different predis-
posing associations of DRB1, DQB1 or DPB1 alleles were detected in SSc with ACA or ATA.
We tested whether HLA class II alleles were associated with ACA positive lcSSc, ACA nega-
tive lcSSc, ATA positive dcSSc, or ATA negative dcSSc (S5 Table). The predisposing or protec-
tive associations of DRB1, DQB1 or DPB1 alleles were mainly detected in ACA positive lcSSc
or ATA positive dcSSc, suggesting that HLA class II alleles specifically influence the production
of antibodies rather than the development of clinical subtypes of SSc.
Fig 1. Associations of amino acid residues in the DRβ (A, D, G), DQβ (B, E, H), or DPβ (C, F, I) chain with SSc (A, B, C), anti-centromere antibody-
positive [ACA(+)] SSc (D, E, F), and anti-topoisomerase I antibody-positive [ATA(+)] SSc (G, H, I). Corrected P (Pc) values were calculated by
multiplying the P value by the number of amino acid residues tested. Associations were established by Fisher’s exact test using 2X2 contingency tables.
Predisposing associations are indicated by filled circles and protective associations by open circles.
doi:10.1371/journal.pone.0154255.g001
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Certain amino acid residues in the HLA-DRβ, DQβ, and DPβ chains are
associated with SSc, or SSc with ACA or ATA
Finally, we analyzed the association with SSc with respect to each amino acid residue in the
HLA-DRβ, DQβ, and DPβ chains. Serine at position 13 (13S, P = 2.06X10-6, OR = 0.49,
Pc = 7.00X10-5, 95% CI 0.36–0.66) in the DRβ chain showed a strong protective association with
SSc (Fig 1A, open circles). Glutamic acid at position 45 (45E, P = 0.0009, OR = 0.56, Pc = 0.0291,
95% CI 0.40–0.79) in the DQβ chain showed a protective association with SSc (Fig 1B, open cir-
cle), whereas aspartic acid at position 57 (57D, P = 0.0005, OR = 1.64, Pc = 0.0092, 95% CI 1.24–
2.17) in the DPβ chain showed a predisposing association with SSc (Fig 1C, filled circle).
We also analyzed the association with SSc with ACA with respect to each amino acid residue
in the HLA-DRβ, DQβ, and DPβ chains. Phenylalanine at position 47 (47F, P = 3.43X10-8,
OR = 0.37, Pc = 1.17X10-6, 95% CI 0.26–0.53) in the DRβ chain showed strong protective asso-
ciations with SSc with ACA (Fig 1D, open circles). Glutamic acid at position 45 (45E,
P = 1.05X10-5, OR = 0.32, Pc = 0.0003, 95% CI 0.18–0.55) in the DQβ chain showed protective
associations with SSc with ACA (Fig 1E, open circle). No statistically significant association
was found for amino acid residue in the DPβ chain.
In addition, we analyzed the association with SSc with ATA with respect to each amino acid
residue in the HLA-DRβ, DQβ, and DPβ chains. Serine at position 13 (13S, P = 1.52X10-6,
OR = 0.29, Pc = 5.16X10-5, 95% CI 0.17–0.50) in the DRβ chain showed a strong protective
association with SSc with ATA (Fig 1G, open circle), whereas alanine at position 71 (71A,
P = 9.37X10-7, OR = 2.83, Pc = 3.19X10-5, 95% CI 1.86–4.31) in the DRβ chain showed a strong
predisposing association with SSc with ATA (Fig 1G, closed circle). Histidine at position 30
(30H, P = 1.33X10-7, OR = 0.22, Pc = 4.11X10-6, 95% CI 0.12–0.42), and tyrosine at position 87
(87Y, P = 1.32X10-7, OR = 0.22, Pc = 4.11X10-6, 95% CI 0.12–0.42) in the DQβ chain showed a
protective association with SSc with ACA (Fig 1H, open circle). Aspartic acid at position 57
(57D, P = 6.66X10-15, OR = 5.44, Pc = 1.13X10-13, 95% CI 3.49–8.48), valine at position 76
(76V, P = 2.20X10-14, OR = 5.27, Pc = 3.74X10-13, 95% CI 3.39–8.18) in the DPβ chain showed
a predisposing association with SSc (Fig 1I, filled circle). Thus, association analysis suggested
roles for specific amino acid residues in the HLA-DRβ, DQβ, and DPβ chains.
Discussion
Several studies have noted predisposing associations ofHLA class II alleles with SSc
[6,8,9,13,14]. However, few studies for theHLA protective association have been validated in
SSc. DRB107:01, DRB115:01, DQB102:02, andDQB106:02 were protectively associated with
European SSc [6], andDRB101:01, DRB104:06, DRB107:01, andDPB102:01 were with Chi-
nese SSc [13,14]. The present study reports significant protective associations of the four alleles,
DRB113:02, DRB114:06, DQB103:01, andDPB102:01, with Japanese SSc (Table 2), though
these protective associations except forDPB102:01 were not observed in previous studies. A
lower frequency of DR6 alleles in Asian patients with SSc has been reported, so far [9,13]. The
protective effect of DR6 seems to be partly mediated byDRB113:02, which is a common protec-
tive allele for several autoimmune diseases in Japanese [21,22,27]. It was known that
DRB114:06 and DQB103:01 are in strong linkage disequilibrium in the Japanese population
[26]. However, conditional logistic regression analysis between them in SSc revealed that they
independently affected on the disease protection (Table 4). Because of the limited sample size of
this study, the observed protective association was modest. The protective association of the
fourHLA class II alleles with SSc should be confirmed in future large scale studies.
In this study, we found a protective association of DQB103:01 with Japanese SSc. This pro-
tective effect was also observed for the SSc with ACA (S3 Table). However, our findings are not
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consistent with a previous report that DQB103:01 is a risk allele for SSc with ACA in the Euro-
pean population [6]. This could be explained by the linkage disequilibrium of DRB11-
DQB103:01 in European populations [7]. However, we cannot rule out the possibility that
there are other causative genes for SSc with ACA in the HLA region in linkage disequilibrium
with the culprit gene in the DQB103:01 haplotype. This possibility could be addressed by com-
parison of the re-sequencing data of the entire HLA region of DQB103:01 haplotype in Japa-
nese and Europeans.
The present study reports a significant predisposing association of DRB101:01 and
DRB110:01, DQB105:01, and DPB104:02 with Japanese ACA positive SSc. The predisposing
associations of DRB110:01 and DRB115:02 with ACA positive SSc in Chinese were reported
[13]. On the other hand, DRB101:01 and DQB105:01 were associated with European ACA
positive SSc [6]. The association of DPB104:02 with Japanese ACA positive SSc was also
reported [9]. Our findings are consistent with these previous reports. The higher haplotype fre-
quency of DRB101:01-DQB105:01 and DRB110:01-DQB105:01 in the Japanese population
suggests an important role of DQB105:01 allele in the pathogenesis of ACA positive SSc in
Japanese [26]. No associations with DQB126 epi including DQB103:01 and DQB106:01 were
detected in the present study, suggesting that no DQB126 epi alleles other than DQB105:01
are risk factors for ACA positive SSc in Japanese.
In the present study, the carrier frequencies of the DRB115:02, DQB106:01, DPB103:01,
and DPB109:01 alleles were higher in SSc patients with ATA. Associations between
DRB115:02, DQB106:01, and DPB109:01 and the presence of ATA have been reported in
Japanese SSc patients [9]. The predisposing association of DRB115:02, DRB116:02,
DPB103:01 and DPB113:01 with ATA positive SSc in Chinese was also reported [13,14].
DRB111:04, DQB103:01, and DPB113:01 were strongly associated with ATA positive SSc in
European descents [6]. The predisposing alleles in our study are overlapping with those
reported in the previous reports.
We revealed that amino acid residues 13, 32 and 71 of the HLA-DRβ chain were protectively
associated with SSc (Fig 1A). Amino acid residues 13, 32 and 71 form the HLA-DR peptide-
binding groove [28], suggesting the involvement of peptide antigens bound to specific
HLA-DR molecules in controlling the prevention of SSc. It was also found that other amino
acid residues of the DRβ, DQβ, or DPβ chains were associated with SSc with ACA or ATA (Fig
1D–1I), though they are different from the results from the previous study in European popu-
lations [5]. These would be reflected by the ethnic differences of susceptible and protective
HLA alleles [2,6,7]. This information suggests that peptide antigens loaded on specific HLA
alleles controlled the generation of autoantibodies.
Because the distribution of HLA alleles in other ethnic populations is different from the Jap-
anese, the role of someHLA class II alleles in SSc in other populations should be determined.
Thus, the present study identified protective associations ofHLA class II alleles with Japanese
SSc; our findings support independent protective roles for the four class II alleles, DRB113:02,
DRB114:06, DQB103:01, and DPB102:01, in the pathogenesis of SSc.
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